Donepezil-Associated Urinary Retention
Donepezil can be associated with urinary retention as a serious adverse reaction. [1]
The cholinesterase-inhibitor class has systemic cholinergic effects that can affect lower urinary tract function. [2]
Evidence Supporting Urinary Retention
Postmarketing and labeling information for donepezil includes urinary retention (reported as “inability to empty bladder” or urinary retention-related events). [1]
Donepezil safety summaries similarly list urinary retention as an uncommon but potentially severe adverse event. [3]
Clinical Presentation
Urinary retention may present as inability to empty the bladder or worsening difficulty with urination. [1]
Urinary retention can occur alongside other urogenital symptoms such as urinary urgency or dysuria as part of the reported lower urinary tract adverse-effect profile. [1]
Risk Context
Urinary symptoms may be more likely in patients with baseline bladder outlet obstruction risk factors, including prostate hypertrophy, as urinary tract adverse events are described in labeling for donepezil. [1]
Management Approach
Urgent evaluation is indicated when urinary retention is suspected after starting or dose-increasing donepezil, including assessment for bladder distention and obstructive uropathy. [1]
Discontinuation or medication change is typically considered when urinary retention is attributed to donepezil based on adverse-event severity and clinical course. [1]
When to Seek Emergency Care
Emergency care is indicated for acute urinary retention with severe lower abdominal pain, inability to void, or signs of complications. [1]